Novel single day premedication regimen for prevention of paclitaxel- induced hypersensitivity reaction

×

Error message

User warning: The following theme is missing from the file system: journalijdr. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1138 of /home2/journalijdr/public_html/includes/bootstrap.inc).

International Journal of Development Research

Volume: 
07
Article ID: 
8067
3 pages
Research Article

Novel single day premedication regimen for prevention of paclitaxel- induced hypersensitivity reaction

Roshan Koshy Jacob, Shashidhar V Karpurmath, Manjunath I Nandennavar and Sunit Lokwani

Abstract: 

Paclitaxel is one of the most active chemotherapy agents for the treatment of ovarian and other gynecologic cancers. Hypersensitivity reactions (HSR) remain one of the major clinical concerns in the use of paclitaxel. This report is a retrospective study assessing the rates of hypersensitivity in patients who received paclitaxel in Vydehi Institute of Medical Sciences and Research centre, Bangalore from May 2015 to July 2016. All patients received 2 doses of INJ Dexamethasone 8 mg, Inj Ranitidine 50 mg and Inj Pheniramine Maleate 44.5 mg 3 hours apart on the day of chemotherapy. The primary outcome measure was rate of hypersensitivity. In this series, novel single day premedication for Paclitaxel appeared to be associated with lower rate of hypersensitivity than the conventional premedication regimen.

Download PDF: